Supplementary Materials

The PDF file includes:

  • Fig. S1. Characterization of ALPPL2 tissue expression and ALPPL2 CAR specificity.
  • Fig. S2. Characterization of ALPPL2 synNotch–regulated CAR expression.
  • Fig. S3. Activation and proliferation of antigen-stimulated ALPPL2 synNotch CAR circuits.
  • Fig. S4. Cytokine production by CAR and synNotch CAR circuit T cells.
  • Fig. S5. Polyfunctionality of CAR and synNotch CAR circuit T cells.
  • Fig. S6. SynNotch CAR circuit T cells exhibit multi-antigen specificity and paced tumor elimination.
  • Fig. S7. Development of tumor cell lines expressing titratable antigen densities and synNotch CAR circuit sensitivity toward mesothelin.
  • Fig. S8. Phenotypic analysis of CAR and synNotch CAR T cells before antigen exposure.
  • Fig. S9. Impact of CAR expression on tonic signaling.
  • Fig. S10. SynNotch CAR circuits regulate the evolution of T cell differentiation before and after antigen stimulation.
  • Fig. S11. Persistence of CAR T cells and synNotch CAR circuit T cells in treated M28 tumor–bearing mice.
  • Fig. S12. SynNotch enhancements for CAR T therapy.
  • Table S1. ALPPL2 expression in solid tumors.
  • Table S2. Tissue specificity of ALPPL2 expression.
  • Table S3. IHC of MCAM expression in FFPE mesothelioma tissue arrays.
  • Table S4. MCAM coexpression in ALPPL2-positive mesothelioma.
  • Table S5. Antibodies used for immunophenotypic analysis.

[Download PDF]

Other Supplementary Material for this manuscript includes the following: